Equity Profile

CRNX

Crinetics Pharmaceuticals, Inc.

Health CarePharmaceuticals$8.9B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Crinetics Pharmaceuticals, Inc. is a healthcare company focused on developing innovative therapies for rare endocrine diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market presence and sustain operations.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CRNX Q2-2026 Earnings Preview

Context

Company Snapshot

Crinetics Pharmaceuticals, Inc. is a healthcare company focused on developing innovative therapies for rare endocrine diseases. With a market cap of $9 billion, its work is vital as it addresses unmet medical needs in the pharmaceutical industry.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-3.44%

Avg Stock Reaction

+1.78%

Last Quarter Recap

In Q1-2026, Crinetics reported an EPS of -$1.23, slightly missing expectations. The stock reacted positively, gaining 4.27% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Crinetics' upcoming earnings report, especially given the recent stock performance following earnings announcements.

Bull Case

If Crinetics can demonstrate improved clinical trial results or better-than-expected EPS, it could lead to a significant upward revision in stock price.

Bear Case

Conversely, if the company reports wider losses or delays in clinical trials, it could lead to a sharp decline in investor confidence and stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

EPS is a critical measure of profitability, and any significant deviation from expectations could impact investor sentiment.

What updates can management provide on ongoing clinical trials?

Progress in clinical trials can greatly influence the company's future prospects and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Crinetics to exceed EPS expectations based on recent trial progress.

Supporting Evidence

Options are pricing a 17.74% move, suggesting expectations of volatility that may not align with actual performance.

The company's recent stock performance following earnings indicates a potential for positive surprises.

Key Risk

If EPS comes in better than -$1.10, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for improved financial performance against the backdrop of ongoing clinical trials.

Bull Confirmed If

A reduction in EPS loss to below -$1.10 would indicate improved financial health.

Bear Confirmed If

An EPS loss greater than -$1.30 would confirm ongoing financial struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±17.74%

Historical Avg

±2.9%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±17.7% while CRNX has averaged ±2.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

59.7%

Calls (600)P/C Ratio: 0.92Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Crinetics beats expectations, history suggests a potential stock increase of around 1.42%, confirming bullish sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may see minimal movement as investors digest the news.

Miss

A miss could lead to a decline in stock price, with historical patterns indicating an average drop of around 1.90%.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on clinical trial timelines and results.
2Any guidance on future revenue expectations.
3Management's commentary on cost management strategies.
4Insights into market demand for their therapies.
5Discussion of any regulatory developments affecting their products.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Crinetics Pharmaceuticals, Inc. is a healthcare company focused on developing innovative therapies for rare endocrine diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market presence and sustain operations.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CRNX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-3.44%

Avg Stock Reaction

+1.78%

Last Quarter Recap

In Q1-2026, Crinetics reported an EPS of -$1.23, slightly missing expectations. The stock reacted positively, gaining 4.27% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Crinetics' upcoming earnings report, especially given the recent stock performance following earnings announcements.

Bull Case

If Crinetics can demonstrate improved clinical trial results or better-than-expected EPS, it could lead to a significant upward revision in stock price.

Bear Case

Conversely, if the company reports wider losses or delays in clinical trials, it could lead to a sharp decline in investor confidence and stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

EPS is a critical measure of profitability, and any significant deviation from expectations could impact investor sentiment.

What updates can management provide on ongoing clinical trials?

Progress in clinical trials can greatly influence the company's future prospects and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Crinetics to exceed EPS expectations based on recent trial progress.

Supporting Evidence

Options are pricing a 17.74% move, suggesting expectations of volatility that may not align with actual performance.

The company's recent stock performance following earnings indicates a potential for positive surprises.

Key Risk

If EPS comes in better than -$1.10, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for improved financial performance against the backdrop of ongoing clinical trials.

Bull Confirmed If

A reduction in EPS loss to below -$1.10 would indicate improved financial health.

Bear Confirmed If

An EPS loss greater than -$1.30 would confirm ongoing financial struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±17.74%

Historical Avg

±2.9%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±17.7% while CRNX has averaged ±2.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

59.7%

Calls (600)P/C Ratio: 0.92Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Crinetics beats expectations, history suggests a potential stock increase of around 1.42%, confirming bullish sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may see minimal movement as investors digest the news.

Miss

A miss could lead to a decline in stock price, with historical patterns indicating an average drop of around 1.90%.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on clinical trial timelines and results.
2Any guidance on future revenue expectations.
3Management's commentary on cost management strategies.
4Insights into market demand for their therapies.
5Discussion of any regulatory developments affecting their products.